BUSINESS
Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief
Nxera Pharma has set out a global sales target of 50 billion yen by 2030, but the company’s new Japan president calls it “a conservative figure,” noting that the challenge will be how to surpass this line. Makoto Sugita, who…
To read the full story
Related Article
- Nxera Pharma Eyes 50 Billion Yen in Global Revenue by 2030: CEO
November 7, 2024
- Ex-BMS Exec Sugita Tapped as President of Nxera Pharma Japan
October 2, 2024
BUSINESS
- AbbVie Japan Says Sales-Doubling Plan on Track as Revenue Climbs 13.5%
June 3, 2026
- FunPep, Crafton Join Forces on Therapeutic mRNA Vaccines
June 3, 2026
- Shionogi’s Xocova Scores US FDA Nod for COVID-19 PEP
June 3, 2026
- J&J’s Tremfya Now Available for Self-Injection in IBD
June 2, 2026
- J&J Taps Leading Cancer Centers to Bolster Japan Trial Environment
June 2, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





